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Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degeneration involves several 
neurotransmission systems, resulting in a heterogeneous disease characterized by motor and non-motor symptoms. PD causes 
progressive disability that responds only to symptomatic therapies. Future advances include neuroprotective strategies for 
use in at-risk populations before the clinical onset of disease, hence the continuing need to identify reliable biomarkers 
that can facilitate the clinical diagnosis of PD. In this evaluative review, we summarize information on potential diagnostic 
biomarkers for use in the clinical and preclinical stages of PD.
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Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer’s disease: the inci-
dence rate is 8–18 per 100,000 person-years in prospective 
population-based studies and the prevalence increases with 
age, the main known risk factor (Lee and Gilbert 2016). 
Typical PD symptoms include motor features (bradykinesia, 
postural disturbances, rigidity or tremor or both) and non-
motor features (hyposmia, sleep disorders, autonomic, neu-
ropsychiatric and sensory symptoms). The diagnosis of PD 
depends mostly on clinical motor findings (Postuma et al. 
2015), which appear when half of the substantia nigra (SN) 
dopamine neurons are lost (Cheng et al. 2010). PD is, there-
fore, often diagnosed clinically when disease progression 
is already advanced. Hence the diagnosis is notably inac-
curate (from nearly 74% accuracy reached by nonexperts, to 
80–84% by movement disorder experts) (Rizzo et al. 2016). 
Difficulties arise mainly in distinguishing PD from other par-
kinsonisms. To date, no treatment exists for PD; medications 
and surgery aim merely to control symptoms for several 
years. Current treatment strategies focus on dopamine 
replacement to correct or at least partially correct motor 
signs caused by dopamine deficiency. The key neuropathol-
ogy in PD is Lewy body deposition (abnormal aggregates 
of a misfolded protein called α-synuclein) and consequently 
neuronal dysfunction, involving many other brain areas and 
neurotransmitter systems. In their early research, Brack et al. 
proposed a staging scheme based on rostro-caudal patho-
logical progression (Braak et al. 2003). In this study, they 
suggested that in the earliest stages, PD damage is confined 
to non-dopaminergic structures in the lower brainstem, the 
olfactory bulb or perhaps the peripheral autonomic nervous 
system, accounting for the early appearance of non-motor 
symptoms (Chaudhuri et al. 2011). This non-motor theory 
has disadvantages because it applies mainly to the subset of 
patients with young onset and long disease duration. Equally 
controversial is the connection between Lewy pathology and 
clinical parkinsonian features (Rietdijk et al. 2017).
At present, we lack standardized international criteria 
supporting PD diagnosis at a preclinical stage: research 
efforts are, therefore, seeking ways to detect biomarkers 
for the early diagnosis of PD. Research in recent years, 
prompted by epidemiological data on risk factors and pro-
dromal biomarkers, has proposed diagnostic criteria based 
upon the likelihood of prodromal disease (with 80% cer-
tainty) but applicable only for research purposes (Berg 
et al. 2015). Their usefulness consists in defining target 
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populations for eventual future disease-prevention trials with 
disease-modifying drugs (Mahlknecht et al. 2016).
Definition of biomarkers
Although the term ‘biomarker’ is often used indiscrimi-
nately to describe any change in gene or protein expression 
the NIH Biomarkers Definitions Working Group defines it 
more appropriately as “a characteristic that is objectively 
measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention” (Biomarkers Defi-
nitions Working Group 2001).
Several excellent reports have examined how to use and 
qualify clinical biomarkers (Freeman et al. 2010). Bio-
markers for PD could for example be used to diagnose 
PD (diagnostic markers), predict the risk of PD or dis-
ease progression (prognostic markers), describe disease 
severity (staging markers) and support treatment choice 
(theragnostic markers). Diagnostic markers can be useful 
to recognize PD before motor features become evident or 
when motor or non-motor signs or both are still insufficient 
to define disease (prodromal phase) or even to detect an 
asymptomatic population at risk of PD in whom neurode-
generation is expected to begin (preclinical phase). Diag-
nostic markers could also help to differentiate PD from 
other parkinsonian syndromes, insofar as misdiagnosis 
often takes place early in the disease and diagnostic confir-
mation needs autopsy reports. The difficulty in identifying 
early diagnostic criteria for PD depends on the fact that no 
real biomarker can yet predict illness onset.
In this evaluative review, we will, therefore, summarize 
the most referred and promising diagnostic biomarkers 
now under investigation for PD (Tables 1, 2).
Clinical signs and symptoms
The most important clinical diagnostic and prognostic 
markers in PD are still the motor symptoms, crucial also 
for monitoring the response to symptomatic therapy. The 
physical examination finding that best correlates with 
nigrostriatal dopaminergic loss and the core sign of par-
kinsonism is bradykinesia, associated with rest tremor or 
rigidity, or both (Postuma et al. 2015). Since Hoen and 
Yahr first described it in 1967, several studies suggested 
that tremor is a progression marker for benign PD (Marras 
et al. 2002). Others underline differences in the clinical 
course and prognosis between tremor-dominant (TD) and 
postural instability gait disorder (PIGD) or akinetic-rigid 
subtypes (Stebbins et al. 2013), who show a more rapid 
clinical progression and have an increased risk to develop 
disability and dementia (Rajput et al. 2009). Motor impair-
ment is routinely assessed with a clinical rating scale, such 
as the Unified Parkinson’s disease rating scale (UPDRS) or 
revised version of the Movement Disorder Society (MDS-
UPDRS). The disease-modifying efficacy of a therapy 
that also provides a symptomatic effect is troublesome to 
detect. An acute levodopa challenge supports the clinical 
diagnosis of PD with a specificity that seems to increase in 
patients with mild symptoms (Merello et al. 2002).
Subthreshold parkinsonism detected by experts in PD 
assessment (i.e., UPDRS > 3 excluding tremor action) is 
considered as a marker of prodromal disease that is unlikely 
to progress to manifest PD (Berg et al. 2015).
Because PD measures are subjective and rater-depend-
ent, two decades ago researchers began to consider using 
objective monitoring systems, which lead to the develop-
ment of wearable technology (such as watches, bracelets) 
and connected devices (such as smartphone apps). These 
tools gather valuable early diagnostic data on kinematic vari-
ables in a non-clinical setting, potentially enhancing clinical 
diagnosis and care (Del Din et al. 2016; Zhan et al. 2018).
Besides motor features, some non-motor symptoms 
(NMS) appear specific for PD as well as for other synu-
cleinopathies, neurodegenerative diseases characterized 
by the abnormal accumulation of α-synuclein aggregates 
in the nervous system (Lewy body dementia and multiple 
system atrophy). NMS may appear in a prodromal disease 
stage (Chaudhuri and Schapira 2009). Early NMS reflect 
degeneration in extra-nigral areas before the loss of nigral 
dopamine neurons and include olfactory dysfunction, REM 
sleep behaviour disorder, autonomic dysfunction (such as 
constipation), and depression (Berg et al. 2013) (Fig. 1).
Olfactory dysfunction
The olfactory system is one of the earliest structures affected 
in PD and hyposmia is one of the NMS in PD (Xiao et al. 
2014). The “olfactory vector hypothesis” supports the idea 
that the olfactory pathway could be an entry-point for cer-
tain pathogens with a putative role in starting the disease 
(Doty 2008). Given that this system’s particular anatomy 
enables it to bypass the blood–brain barrier, some have also 
suggested that PD might be a primary olfactory disorder 
(Hawkes et al. 1999; Doty 2008). Some findings neverthe-
less excluded neurodegeneration involving dopamine neu-
rons in the olfactory bulb in patients with PD; some evidence 
even indicates a paradoxical increase in dopamine neurons in 
some PD patients compared with controls (Duda 2010). Not 
all patients with PD experience olfactory problems, although 
sensitivity rates range from 45% up to 96% (Haehner et al. 
2009). These differences may reflect the type, or the com-
bination of olfactory tests used or both, and their normative 
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Table 1  Major diagnostic biomarkers under investigation in Parkinson’s disease
MRI magnetic resonance imaging, N/A not available
a Low = visit or questionnaire; moderate = requires a low-cost examination (< 200 US $); high = requires an expensive evaluation (> 200 US $) 
Postuma and Berg (2016)
Markers Diagnostic test sta-
tistics
References Testing  costa Invasiveness Disadvantages com-
ments
Clinical biomarkers
 Mild motor symp-
toms
SE 89.3%
SP 65.8%
Rizzo et al. (2016) Low Low Late indicators
 Levodopa challenge SE 70.9%
SP 81.4%
Merello et al. (2002) Low Low Late indicator
 Olfactory dysfunc-
tion
SE 60–100%
SP 72–94%
Berg et al. (2015) Low Low Lack of standardization 
in olfactory tests
Unclear lead time
 REM behaviour sleep 
disorder
SE 50%
SP 40–65% within 
10 years
Gagnon et al. (2002) 
and Postuma et al. 
(2009)
Low for screens
Moderate for PSG
Low Differences between 
clinically or PSG-
proven
 Excessive daytime 
sleepiness
SE 21–23%
SP 87–92
Berg et al. (2015) Low Low Very low predic-
tive positive value 
(0.5–3.7%)
 Constipation SE 10–50%
SP 75–96%
Berg et al. (2015) Low Low Very common in the 
general population
 Depression SE 0.2–45%
SP 75–99.9
Berg et al. (2015) Low Low Very common in the 
general population
 Visual dysfunctions N/A Armstrong (2015) Low Low Few studies
Fluid biomarkers N/A Moderate or high Minimally or moder-
ately invasive
Few studies or scarce 
reproducibility
Tissue biomarkers Depends on harvesting 
method
Berg et al. (2015) Moderate or high Moderately invasive Few studies or scarce 
reproducibility
Imaging biomarkers
 MRI 3 T (7-Tesla) SE 94.6% (97.7%)
SP 94.4% (94.6%)
Mahlknecht et al. 
(2017)
High Low Available only in a 
research context
 DAT imaging In hyposmic subjects: 
SE 77.8%
SP 94.2% In RBD 
cohort SE 53.6% SP 
98.4%
Iranzo et al. (2010) and 
Jennings et al. (2014)
High Minimally invasive High-risk population 
bias in main studies
Not useful to differenti-
ate between neurode-
generative parkinso-
nian disorders
 Substantia nigra 
hyperechogenicity
SE 44.4–82.4%
SP 82.5–87.2%
Berg et al. (2013) and 
Iranzo et al. (2014)
Moderate or high Low 10–20% people have 
an inadequate bone 
window
 Genetic biomarkers Depends on gene 
mutation
Berg et al. (2015) Moderate Minimally invasive Few cases of PD owing 
to pure monogenetic 
mutation; different 
penetrance and age-
dependent expres-
sivity
 Meta-iodo-benzyl-
guanidine cardiac 
scintigraphy
SE 90.2%
SP 81.9%
Chung and Kim (2015) Moderate Minimally invasive May be negative in 
genetic Parkinson
Neurophysiological 
biomarkers
N/A Priori et al. (2004), 
Swann et al. (2015) 
and Wang et al. 
(2016)
Moderate Low Few data on healthy 
controls
Metabolomic biomark-
ers
N/A Chen et al. (2016) and 
Kori et al. (2016)
Moderate or high Minimally invasive Insufficient data
Inflammatory bio-
markers
N/A Chen et al. (2016) Moderate or high Minimally or moder-
ately invasive
Insufficient data
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data. Equally important, the age distribution of PD and 
controls varies between different investigations. Nor can 
we ignore that hyposmia is a common phenomenon during 
aging (Welge-Lüssen 2009): smell dysfunction affects more 
than 50% of people aged 65 years and over and about 75% 
of subjects older than 80 years (Doty et al. 1984). Hypos-
mia can also be the early expression of cognitive disorders: 
some evidence also describes severe olfactory deficits as 
a predictive feature of PD with dementia (PDD) (Takeda 
et al. 2014). Subjective olfactory impairment (through infor-
mation from history-taking or self-reported olfactory ques-
tionnaires) may not overlap with an objective injury and a 
loss of awareness of hyposmia may be associated with early 
cognitive impairment in PD (Kawasaki et al. 2016). Smell is 
less impaired, however, in other common causes of parkin-
sonism (Wenning et al. 1995), in synucleinopathies such as 
multiple system atrophy (MSA), and in tauopathies such as 
corticobasal degeneration (CBD) and progressive supranu-
clear palsy (PSP); an olfactory dysfunction is infrequent also 
in essential tremor (Busenbark et al. 1992). Other studies 
found that PD patients with predominant PIGD lose their 
sense of smell more often than those with TD (Stern et al. 
1994). In conclusion, hyposmia can be useful as a preclini-
cal marker of disease in combination with other biomarkers 
to increase the predictive value but not alone. For example, 
combined assessment of hyposmia, motor asymmetry and a 
typical finding at ultrasound (midbrain hyper-echogenicity) 
could improve diagnostic accuracy in early PD (Poewe and 
Mahlknecht 2012).
REM behaviour sleep disorder
Another early PD feature indicating brainstem involvement, 
supported by the finding of Lewy body pathology, is rapid 
eye movement (REM) sleep behaviour disorder (Boeve et al. 
2007). REM sleep behaviour disorder (RBD) is a parasom-
nia which involves abnormal behaviour caused by a loss of 
the physiological motor inhibition (usually present during 
Table 2  Biomarkers for the prodromal stage, diagnosis and progression of Parkinson’s disease (PD)
MS motor symptoms, NMS non-motor symptoms, RBD REM behaviour sleep disorder, EDS excessive daytime sleepiness, CSF cerebrospinal 
fluid, LRKK2 leucine-rich repeat kinase 2, EGF epidermal growth factor, IGF-1 insulin growth factor, BDNF brain-derived neurotrophic factor, 
GI gastrointestinal, DaTscan dopamine transporter imaging technique, MRI magnetic resonance imaging, f-MRI functional-magnetic resonance 
imaging, FDG-PET fluoro-2-deoxy-d-glucose positron-emission tomography, ERG electroretinogram, VEP visual evoked potential, LFPs long 
field potentials
Prodromal Diagnostic Progression
Clinical
 Slight MS (parkinsonism)
 NMS (hyposmia, RBD, EDS, constipation, 
depression, visual dysfunctions)
Clinical
 MS (parkinsonism)
 NMS (hyposmia, RBD, EDS, constipation, 
depression, visual dysfunctions)
Clinical
 MS (tremor, postural instability)
 NMS (hyposmia, cognitive decline, dysauto-
nomia)
Biological fluids
 Blood (e.g., uric acid)
Biological fluids
 CSF (α-synuclein species, DJ-1, LRKK2, 
metabolites)
 Blood (e.g., uric acid, apolipoprotein A1, 
LRKK2, inflammation factors)
 Saliva (α-synuclein species)
 Urine (biopyrin, LRKK2)
Biological fluids
 CSF (α-synuclein, A ß oligomers, p-tau)
 Blood (e.g., uric acid, EGF, IGF-1, BDNF)
Pathology
 Biopsies (GI tract, salivary glands, olfactory 
mucosa, skin)
Pathology
 Microbiota (gut, oral)
–
Imaging
 Nuclear imaging (nigrostriatal degeneration 
at DaTscan)
 Transcranial ultrasound (substantia nigra 
hyperechogenicity)
Imaging
 Structural imaging (nigral degeneration on 
MRI at ≥ 3 T)
 Functional imaging (remapping of cerebral 
connectivity at f-MRI)
 Nuclear imaging (nigrostriatal degenera-
tion at DaTscan, microglial activation at 
PET imaging, post-ganglionic sympathetic 
nerve damage on cardiac and salivary gland 
scintigraphy)
Imaging
 Functional imaging (hypometabolism patterns 
on FDG-PET)
– Neurophysiology
 Altered ERG, VEP, LFPs
–
– Omics
 Proteomics, genomics, lipidomics, glycomics, 
metabolomics, interactomics
–
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REM sleep); this disorder leads to varying degrees of com-
plex motor activity which ranges from sleep talking to vio-
lent dream enacting behaviours potentially harmful for the 
patient or bed partner. The reference standard to confirm 
RBD is a polysomnogram (PSG). One way to avoid this 
resource-demanding procedure is to interview the patient’s 
partner with specific questionnaires (Al-Qassabi et  al. 
2017). RBD affects 0.38–2.01% of people, but its preva-
lence is higher in synucleinopathies (Jiang et al. 2016) and 
is an early NMS that appears decades before motor involve-
ment not only in PD, but also in dementia with Lewy bod-
ies (DLB), or MSA (Claassen et al. 2010). The presence 
of RBD increases the risk of these neurodegenerative dis-
orders developing in up to 40–65% of patients at 10 years 
(Postuma et al. 2009) and is the prodromal marker with the 
highest positive likelihood ratio (LR): patients with posi-
tive PSG are 130 times more likely than those without to 
have PD. Positive LRs dramatically decrease when RBD is 
assessed by means of screen questionnaire even with > 80% 
specificity, from 130 to 2.2 (Postuma et al. 2015). Despite 
its high specificity, RBD is present in less than half of all 
cases of PD (Gagnon et al. 2002), so it is an early sign with 
scarce sensitivity. In summary, RBD alone is unreliable as a 
diagnostic biomarker. Combining the presence of RBD as a 
prodromic NMS with other markers could further increase 
its predictive value.
Excessive daytime sleepiness
Excessive daytime sleepiness (EDS) consists in the inability 
to maintain wakefulness during the day, with sleep occurring 
unintentionally or at inappropriate times. EDS is among the 
most common sleep-related patient symptoms, affecting an 
estimated 20% of the population (Pagel 2009). It can mani-
fest as primary hypersomnia of central origin or more com-
monly secondary to sleep disorders (for example, sleep dep-
rivation and obstructive sleep apnoea), to medication effects 
or to other medical and psychiatric conditions.
EDS is a common feature in PD and can affect up to 50% 
of patients taking dopamine agonist medication (Hobson 
et al. 2002). A prospective follow-up study of incident clini-
cal PD in men has shown that the presence of EDS increased 
the risk of disease up to threefold (Abbott et al. 2005). EDS 
could also appear during the course of the disease; besides 
the dopamine agonist dose, disparate factors such as male 
gender, poorer night-time sleep, cognitive impairment, hal-
lucinations and autonomic dysfunction, have been associated 
with higher EDS scores over time (Zhu et al. 2016). In two 
population-based studies, EDS showed a positive LR 2.2 to 
predict PD, so despite its low VPP it can be considered a 
prodromal marker (Berg et al. 2015).
Insomnia
Insomnia is defined as the difficulty to initiate or maintain 
sleep or the presence of early awakenings or both problems. 
It is the most common sleep disturbance in PD patients, 
manifesting in up to 80% of cases, and is multifactorial 
(due to neurodegeneration, depression, anxiety, motor 
fluctuations, PD drugs and their withdrawal) (Al-Qassabi 
et al. 2017). Insomnia may arise at any PD stage, but its 
Fig. 1  Parkinson’s disease progression. Non-motor symptoms (NMS) 
may emerge in a pre-motor or prodromal stage reflecting degenera-
tion in extra-nigral areas before the loss of nigral dopamine neurons. 
Conversely, the motor symptoms currently required for diagnosis 
manifest later. From Kalia and Lang (https ://doi.org/10.1016/S0140 
-6736(14)61393 -3) 2015;386:896–912, copyright (2015) with per-
mission from Elsevier
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prevalence seems to increase along with the duration (Loddo 
et al. 2017). Too little evidence is available to justify includ-
ing insomnia as a prodromal marker of PD.
Constipation
A considerably more sensitive early NMS in PD is consti-
pation (Berg et al. 2013), which affects up to 80% of PD 
patients (Noyce et al. 2012). Despite its sensitivity, this 
symptom has a low specificity because it is relatively fre-
quent also in the general population and its prevalence 
increases with age (Higgins and Johanson 2004). A popula-
tion study (Savica et al. 2009) suggested that constipation 
arising also more than 20 years before motor symptom onset 
is associated with an increased risk of PD. The various pub-
lished studies fail to define constipation in a uniform manner. 
A review published in recent years (Knudsen et al. 2017) has 
identified 12 different criteria. Among these, the ROME cri-
teria appear the most valid tool for investigating colonic and 
anorectal dysfunctions (Drossman and Dumitrascu 2006). 
These findings notwithstanding, idiopathic constipation is 
one of the strongest risk factors for PD: men reporting a 
bowel movement frequency of < 1 per day showed an odds 
ratio (OR) for PD of 2.3 compared with those reporting 1 
per day (Abbott et al. 2001).
Colorectal transit time (CTT) is prolonged in approxi-
mately 80% of untreated de novo PD patients, but appears 
uncorrelated with subjective constipation symptoms (Knud-
sen et al. 2017). Hence, CTT studied with radio opaque 
markers may be a potential biomarker for prodromal PD.
Α-synuclein accumulation and other neurodegenerative 
changes in the enteric nervous system, in addition to signs of 
local inflammation, oxidative stress and increased mucosal 
permeability, are associated with prolonged CTT and consti-
pation in the earliest stages of PD (Scheperjans et al. 2015). 
These features, supporting the caudal-rostral progression of 
α-synuclein pathology suggested by Braak et al. (2003), led 
some to hypothesize that such environmental factors could 
act primarily through the gut, implying that gut microbiota 
might play a mediatory role. Subsequent research discover-
ing these gut alterations in PD is only the tip of the iceberg. 
A promising approach for detecting α-synuclein pathology 
could be to take gastrointestinal tract biopsies (Cersosimo 
2015) thus providing a new, although invasive, diagnostic 
biomarker for PD.
Depression
About 35% of patients with PD suffer from severe depres-
sion (Reijnders et al. 2008). Given that depressive symptoms 
may precede the onset of motor symptoms in 30% of cases 
and their incidence increases during the few years preceding 
the diagnosis, depression has a potential role in diagnosing 
pre-motor PD. Depression in PD seems related to multiple 
neurotransmitter dysfunction, involving not only dopamine 
in the substantia nigra, but also serotonin in the raphe nuclei 
and noradrenaline in the locus coeruleus (Borgonovo et al. 
2017). Like constipation, owing to its high prevalence in 
the general population, depression is not specific as a stand-
alone biomarker of prodromal PD, but can coexist with other 
potential markers such as family history and substantia nigra 
hyperechogenicity (Liepelt-Scarfone et al. 2011). Depres-
sion is also tricky to diagnose in a patient with clinically 
manifest PD because it overlaps with motor symptoms, 
such as slowing and bradyphrenia and with other NMS, for 
example sleep and appetite disturbance, loss of concentra-
tion and interest and impaired libido. Patients with PD can 
maintain intact affective responses but may have difficulties 
in translating such feelings into motor phenomena (Rickards 
2005). A disorder often mistaken for depression in PD is 
abulia. Abulia can bias the estimated prevalence rates for a 
depressive syndrome in PD. Abulia is a disorder of dimin-
ished motivation due to damaged connections between the 
anterior cingulate area and striatum, so that abulic patients 
have no desire to do things without getting bored (Heimer 
et al. 2008). Some help in differentiating depression from 
abulia comes from appropriate diagnostic tools (Torbey et al. 
2015).
Cognition
Cognitive impairment in PD is due to a fronto-striatal syn-
drome which mainly affects executive function in milder 
disease stages; a widespread failure in neurotransmitter sys-
tems besides the dopaminergic one, such as noradrenergic, 
serotoninergic and cholinergic systems, is more evident with 
disease progression. Though cognitive decline is a well-
known NMS in the late stages of PD, increasing in paral-
lel with age and PD duration, mild cognitive impairment 
is recognized also in 15–20% of patients in the early PD 
stages; approximately 80% of patients have dementia during 
the disease course (O’Callaghan and Lewis 2017). Cognition 
cannot be considered as a pre-motor biomarker, but it has a 
key role as both a staging and prognostic biomarker, as well 
as in sub-typing and disease stratification. An increase inci-
dence of cognitive impairment is evident in the non-tremor, 
akinetic-rigid phenotype. Executive dysfunction has been 
associated with a more severe gait dysfunction, freezing 
of gait and postural instability, whereas specific cognitive 
domains were differentially related to different PIGD com-
ponents (i.e., visual impairment to a more severe freezing 
of gait, memory impairment to a worse postural instability) 
(Kelly et al. 2015). The NMS most associated with cogni-
tive decline are early visual hallucinations, RBD, hypos-
mia and depression. Dementia associated with at least one 
feature among fluctuating cognition, visual hallucinations, 
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RBD and parkinsonism allow a diagnosis of DLB. No major 
clinical differences exist between DLB and PDD, both of 
which belong both to the Lewy body dementia. The DLB 
Consortium has developed an arbitrary diagnostic distinction 
(McKeith et al. 2017) based on the temporal appearance of 
motor and cognitive symptoms (the “1 year-rule” states that 
cognitive decline manifests before or within a year after the 
onset of parkinsonism in DLB).
Visual dysfunction
Among other NMS, PD patients may have various visual 
disturbances that can be sensitive markers of disease, includ-
ing changes in colour vision and contrast sensitivity possibly 
due to a loss of dopaminergic amacrine retinal cells, and 
difficulties with complex visual tasks (for example men-
tal rotation and emotion recognition) caused by a cortical 
visuoperceptual dysfunction (Weil et al. 2016). In a study 
conducted in 2010, Diederich et al. (2010) noted that defi-
cits in colour and contrast sensitivity seem to discriminate 
early diagnosis of PD within 3 years better than other NMS 
do. Visuo-perceptual deficits rarely arise in other parkin-
sonisms and could serve to distinguish idiopathic PD from 
other diseases. Another visual dysfunction reported in PD 
is a decrease in retinal nerve-fibre layer thickness on optical 
coherence tomography (Moschos et al. 2011). Some evi-
dence also suggests as a retinal biomarker a mathematical 
model quantifying foveal symmetry and breadth (Slotnick 
et al. 2015). More data are needed on the prevalence of 
visual markers in the preclinical stage of PD to allow their 
future use as biomarkers.
Biological fluids
Altered α-synuclein metabolism in the central nervous sys-
tem (CNS) has a central role in the pathogenesis of PD and 
may manifest also in the periphery. Studies conducted in 
recent years have focused on determining α-synuclein spe-
cies in different fluids and tissues. Although α-synuclein is 
mainly expressed by neuronal cells as a cytoplasmic protein 
in its native form or in aggregated pathological (oligomeric, 
phosphorylated) forms (Abd-Elhadi et al. 2016), because it 
also has access to the extracellular space it can be detected 
in cerebrospinal fluid (CSF). Because observations in recent 
years have linked CSF α-synuclein levels to PD, some have 
speculated that they could reflect disease severity (Hall 
et al. 2015), though others disagree (van Dijk et al. 2014). 
CSF α-synuclein levels seem to decrease with age also in 
healthy subjects (Koehler et al. 2015). Total α-synuclein is 
decreased in synucleinopathies, but is not specific for PD, 
whereas data for aggregated forms of α-synuclein yield 
controversial results (Andersen et al. 2016). Phosphorylated 
α-synuclein combined with total α-synuclein concentrations 
in CSF may help in distinguishing PD from atypical parkin-
sonisms (MSA, PSP) (Wang et al. 2012), but further studies 
are needed in independent cohorts of patients.
Other major potential CSF biomarkers studied include 
DJ-1, whose mutations are a rare cause of PD (Hong et al. 
2010), Aβ42, which seems to correlate with cognitive 
impairment, and different forms of tau and neurofilament 
light chains that might help to differentiate PD from other 
α-synucleinopathies (such as MSA) and primary tauopa-
thies (PSP and CBD) (Magdalinou et al. 2014). Despite 
these encouraging findings, future research needs to seek 
more data. Owing to the degeneration in catecholaminergic 
neurons, some report lower levels of dopamine metabolites, 
such as dihydroxyphenyl acetate (DOPAC) and homovan-
illic acid (HVA) and noradrenergic metabolites including 
dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxy-
phenylglycol (MHPG) in CSF from patients with PD than 
from controls (Lee et al. 2017). In a case–control study (217 
vs. 26 subjects) that lacked healthy elderly controls, others 
proposed as a possible state and trait biomarker for PD, the 
ratio of the purine metabolite xanthine over HVA (LeWitt 
et al. 2011).
Because lumbar puncture is an invasive procedure, and 
increasing evidence suggests that α-synuclein passes through 
the blood–brain barrier, recent efforts concentrate on assay-
ing it in plasma rather than CSF. This research has yielded 
ambiguous results owing to the various assay techniques, the 
different protein forms assayed (total, oligomeric and phos-
phorylated) and the small populations enrolled (El-Agnaf 
et al. 2006; Lee et al. 2006; Li et al. 2007; Duran et al. 2010; 
Shi et al. 2010; Foulds et al. 2013); others also suggested 
gender-related differences in plasma α-synuclein expression 
in PD (Caranci et al. 2013). Blood has been a target also 
for assaying DJ-1, a protein involved in the pathogenesis of 
PD through oxidative stress and mitochondrial dysfunction. 
Assaying total DJ-1 levels in PD patients has produced con-
troversial results (Hong et al. 2010; Shi et al. 2010), whereas 
fractions of specific DJ-1 isoforms differed in PD patients 
and healthy controls. Although some researchers suggested 
high oxidized DJ-1 protein levels in red blood cells as a 
potential biomarker for early PD, the study enrolled a small 
sample (Ogawa et al. 2014). Fractions of specific isoforms 
of 4-hydroxy-2-nonenal-modified DJ-1 differed significantly 
in patients with PD and controls (Lin et al. 2012) and within 
stages of PD, suggesting a potential as a staging biologi-
cal marker of disease. These findings merit confirmation in 
further studies.
Another blood biomarker is serum urate (one of the major 
anti-oxidants in humans), levels of which have been known 
for 20 years to be lower in PD than in healthy persons (Davis 
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et al. 1996). Urate has been proposed as a staging marker in 
the PRECEPT cohort (Schwarzschild et al. 2008): clinical 
progression was slower in a cohort of 399 de novo PD men 
(but not in women) with the highest serum urate level than 
in men with the lowest levels.
Other unbiased blood-based biomarkers for PD include 
epidermal growth factor, whose level correlates with cogni-
tive performance in PD (Chen-Plotkin et al. 2011) and apoli-
poprotein A1, which seems to decrease the risk of develop-
ing the disease. Apolipoprotein-1 negatively correlates with 
dopaminergic denervation in subjects with hyposmia and a 
family history of PD (Qiang et al. 2013) and its level has a 
maximum sensitivity of 71% and specificity of 60% in differ-
entiating patients with PD from healthy controls (Swanson 
et al. 2015).
Another potentially readily accessible body fluid is saliva; 
two studies reported a reduction in total α-synuclein lev-
els and elevation in oligomeric α-synuclein and DJ-1 in the 
saliva of PD patients compared with controls (Masters et al. 
2015; Vivacqua et al. 2016), confirming previously reported 
results (Stewart et al. 2014).
The search for fluid PD biomarkers focusses also on the 
urine, as in the BIOFIND study (Kang et al. 2016). In a 
case–control study (92 patients vs. 65 healthy controls) oth-
ers found elevated excretion of urinary biopyrin, an oxida-
tive metabolite of bilirubin (Luan et al. 2015), but this prom-
ising finding remains unreplicated.
Pathology
Given the known presence of extr-anigral PD pathology, 
research efforts have focused on demonstrating Lewy type 
α-synuclein deposition in peripheral tissues, especially in 
olfactory bulb, gastrointestinal tract (GI) (such as subman-
dibular gland, oesophagus, stomach and colon) and skin 
(Lee et al. 2017). Yet tissue biopsies are unlikely to help 
distinguish PD from other synucleinopathies (Mehta and 
Adler 2016). A review published in recent years (Schnei-
der et al. 2016) evaluated the sensitivity and specificity of 
total and phosphorylated α-synuclein detected in biopsies 
from various tissues from PD patients, despite the difficul-
ties in analysing the many disparate harvesting methods 
(such as vivo vs. post-mortem samples) used in the vari-
ous studies. Tissues obtained from the GI tract and sali-
vary glands showed a better sensitivity and specificity for 
total α-synuclein than did skin and or olfactory mucosa or 
bulb, the most promising tissue biomarker for PD, whereas 
phosphorylated α-synuclein resulted inadequate. This find-
ing is not surprising given that the gut could be a starting 
point for PD through which the disease may spread along 
the brain–gut axis (Mulak and Bonaz 2015). Some obser-
vations imply that α-synuclein pathology in peripheral 
autonomic neurons in the gastrointestinal apparatus may 
precede CNS pathology (Greene 2014). Another potential 
gut biomarker emerges from studies investigating faecal 
microbiome (brain-gut-microbiota axis), changes in whose 
complex equilibrium can be linked to the development of 
several diseases, including PD. Nine studies over recent 
years have suggested an intestinal dysbiosis in PD due to an 
imbalance in the bacterial strains in favour of pro-inflam-
matory species, (Scheperjans 2017). Indeed, GI dysfunc-
tion manifests in over 80% of PD subjects. An inflammatory 
condition, associated with a reduction in intestinal cell adhe-
sion (Clairembault et al. 2015), may result in a dysfunction 
involving the intestinal barrier (leaky gut syndrome). These 
changes may be the gateway allowing synuclein pathol-
ogy to spread through the enteric nervous system toward 
the CNS, as the Braak hypothesis suggested (Braak et al. 
2003); as a possible mechanism, others have postulated 
prion-like propagation (Chauhan and Jeans 2015) (Fig. 2). 
All the studies published until now have shown significant 
differences between the microbiota in established PD and 
controls favouring proinflammatory species in the patients’ 
group (Tremlett et al. 2017). Combined with other measures, 
these distinctions may help in developing clinically useful 
microbial biomarkers for PD. Longitudinal studies starting 
in the premotor phase would help to investigate the causality 
of such alterations. Evidence obtained in recent years under-
lines that alterations in gut microbiome precede the motor 
symptoms of PD, given that they were found also in RBD 
(Heintz-Buschart et al. 2017), the NMS associated with the 
major likelihood to progress to a synucleinopathy.
Oral microbiota seems to differ in bacterial taxa from 
patients with PD compared with controls, whereas nasal 
microbiota were similar in two studies (Pereira et al. 2017; 
Heintz-Buschart et al. 2017). Last, some evidence supports 
assaying α-synuclein deposition in cutaneous autonomic 
nerves (Wang et al. 2013): whether tissue α-synuclein might 
be a marker for disease progression awaits evidence from 
longitudinal studies.
Imaging
Progressive dopaminergic cell loss in the pars compacta 
(SNpc) is the hallmark of PD and has been studied in detail 
histologically (Jellinger 2012). Unlike conventional mag-
netic resonance imaging (MRI) acquired with a 1 or 1.5 T 
scanner, ultra-high field 7 T (7 T) MRI, by providing bet-
ter spatial resolution and contrast, can now detect typical 
PD-related changes in SNpc morphology (Lehéricy et al. 
2014) (Fig. 3). Neuropathologically, dopamine-containing 
neurons are distributed in calbindin-poor zones (nigrosomes) 
and in the calbindin-positive region (matrix). Nigrosome-1 
indicates the area of maximal dopamine depletion and is 
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considered the most sensitive pathological marker of neuro-
degeneration in PD (Damier et al. 1999). 7 T MRI displays 
a nigral hyperintensity overlapping the neuropathological 
characterization of nigrosome 1 and is useful to distinguish 
patients with PD from controls owing to a loss of hyper-
intensity areas on T2*-weighted images, present also in 
patients with MSA with predominant parkinsonism and 
PSP (Kim et al. 2016). This marker could reflect the loss of 
melanized neurons and the increase in iron deposition in the 
SNc (Jellinger 2012). A metanalysis (including 10 studies) 
conducted in recent years has established that hyperintensity 
on iron-sensitive dorsolateral nigral MRI sequences can pro-
vide excellent diagnostic accuracy. Its absence demonstrated 
an overall sensitivity and specificity of 97.7 and 94.6% (3 
and 7 T) and of 94.6 and 94.4% (3 T only) for PD vs. con-
trols, thus providing a marker for nigral pathology and for 
a neurodegenerative form of parkinsonian disorders (Mahl-
knecht et al. 2017).
Because the shape of the degenerated nigrosome-1 and its 
surrounding structures in axial imaging on 3 T susceptibil-
ity-weighted MRI in PD has been compared to “a swallow 
tail”, this imaging sign has been proposed as a potential 
diagnostic tool for nigral degeneration in PD (Schwarz et al. 
2014; Gao et al. 2016).
As tools for studying the pathophysiology of PD in vivo, 
functional neuroimaging techniques (fMRI) have promising 
potential. Various methods for analysing data for subjects 
in the resting state (awake without performing any particu-
lar task) have been applied to detect functional connectiv-
ity abnormalities in PD. Dopamine depletion causes a cer-
ebral connectivity remapping across the whole brain (better 
identified through “network-based” and “graph analysis” 
techniques), between specific regions (as shown by “seed-
based” and “effective connectivity” methods) and regional 
anomalies (detected by analysing “regional homogeneity” 
and “amplitude of low-frequency fluctuations”) (Tahmasian 
et al. 2015). Drawbacks currently limiting resting-state fMRI 
as a biomarker for PD include heterogeneous methods and 
insufficient published works using similar methods.
Ample information on dopaminergic denervation comes 
from studies using radiotracer imaging in target structures 
(striatum). These imaging techniques are currently used in 
research and clinical settings to improve the diagnostic accu-
racy for PD in positron emission tomography (PET) and in 
single-photon emission CT (SPECT). The most commonly 
used radioligands are substances contained in presynaptic 
terminals, such as dopa decarboxylase (18F-fluorodopa 
PET), vesicular monoamine transporter type 2 (11C-dihy-
drotetrabenazine) and dopamine transporter (DAT) (123I-β-
CIT SPECT and 99mTcTRODAT-1). DAT density has been 
used as an imaging biomarker for diagnosing PD since 2011, 
because decreased DAT uptake, expressing nigrostriatal 
dopamine neuron loss, is evident before motor features of 
PD appear. Even if DaTSCAN is more sensitive than clini-
cal observations, it lacks diagnostic specificity and cannot 
distinguish PD from other synucleinopathies (MSA, DLB) 
or tauopathies (PSP) nor measure disease progression (Per-
lmutter and Norris 2014). What research needs to do now is 
to develop new tracers based on molecular imaging advances 
thus providing in vivo markers for detecting the underlying 
pathology in PD (Strafella et al. 2017).
Over 90% of PD patients show SN hyperechogenicity 
assessed by transcranial ultrasound compared with 10% of 
controls. Given that this echo-feature remains stable during 
disease progression, it could act as a vulnerability factor for 
PD during patients’ lifetime (Behnke et al. 2010). Because 
SN hyperechogenicity is rarely present in degenerative par-
kinsonisms, it differentiates PD from MSA and PSP (Pilotto 
et al. 2015). Like every ultrasound technique, transcranial 
ultrasound is operator-dependent and in up to 10–20% of 
people is also limited by a poor temporal bone window 
(Behnke et al. 2010).
Meta-iodobenzylguanidine (MIBG) cardiac scintigraphy 
is a technique used to evaluate post-ganglionic presynaptic 
cardiac sympathetic nerves in heart diseases through a false 
neurotransmitter analogous to norepinephrine. Given the 
early sympathetic nerve degeneration during PD, reduced 
cardiac MIBG uptake is a specific marker for Lewy bod-
ies in the autonomic nervous system (Lucio et al. 2013). 
This imaging technique is also useful for differentiating PD 
from MSA, a disease that spares postganglionic sympathetic 
nerves, but pathologically damages preganglionic neurons. 
The MIBG technique can also discriminate between PSP and 
DLB (Lucio et al. 2013). MIBG uptake in the parotid and 
submandibular glands is significantly lower in PD patients 
than in controls (Haqparwar et al. 2016).
Genetics
PD has a multifactorial aetiology including lifestyle, envi-
ronment and genetics and, although only about 10% of 
patients report a positive family history, at least 30% of the 
risk of developing this disorder depends directly on genetic 
factors. Genome-wide association studies have identified at 
least 28 genetic risk loci associated with PD (Taymans et al. 
2017). Few cases of PD are determined by a pure monogenic 
mutation, and also in these patients, PD development cannot 
be taken for granted given the possible low penetrance and 
age-dependent variable expressivity. Age at onset remains 
highly variable even in some carriers of high-penetrance 
mutations (Gasser 2009), such as the α-synuclein gene 
(SNCA) mutation, recognized as a rare cause of autoso-
mal dominantly inherited PD. Leucine-rich repeat kinase 
2 (LRRK2) is another gene of particular interest because 
it induces pleomorphic effects, shows high phenotypic 
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variability among subjects, is also involved in sporadic dis-
ease forms, and is the most common genetic cause of PD in 
the world (Taymans et al. 2017). LRKK2 could be assayed 
in tissues and biofluids relevant to disease and its expres-
sion and phosphorylation levels could have potential as a 
PD-related biomarker (Taymans et al. 2017).
Some monogenic and all sporadic forms of PD share 
the same pathological mechanism, namely intraneuronal 
accumulation of α-synuclein aggregates in Lewy bodies 
and Lewy neuritis in the SNpc and striatum. Mutated genes 
contribute to the pathogenesis of PD through various mecha-
nisms (some still unknown): some by producing misfolded 
proteins (α-synuclein gene duplications, triplications and 
point mutations), others due to dysregulated mitochondrial 
homeostasis (Parkin, DJ1, PINK1 and FBXO7 mutations) 
or to altered lysosomal degradation (ATP13A2 and GBA 
mutations). Other possible candidate biomarkers for PD 
include the aforementioned misfolded proteins, e.g., SNCA 
gene-encoded α-synuclein (Miller and O’Callaghan 2015) 
(Fig. 4).
Neurophysiological biomarkers
In neurophysiological studies conducted in the 1980s, 
researchers describe defects in visual processing involv-
ing dopamine neurons including altered electroretinogram 
(ERG) waves in PD patients: for example, reduced ‘b’ wave 
amplitude at flash ERG, a reduced P50 amplitude and a 
delayed latency at pattern ERG. Visual evoked potentials in 
response to coloured stimuli are also affected in PD; some 
patient’s visual evoked potentials also show a decreased 
amplitude along with an increased latency for all chromatic 
stimuli, above all for blue–yellow horizontal gratings, as 
well as an increased P100 latency to a checkboard stimulus. 
This last finding outlined a delay in visual processing at a 
certain visual system level, maybe involving the choliner-
gic system (Armstrong 2015). No current evidence suggests 
that these neurophysiological biomarkers will accelerate the 
diagnosis of PD.
Subthalamic nucleus local field potentials recorded from 
electrodes implanted intraoperatively in the basal ganglia 
disclosed oscillations in the β frequency range, the range 
that levodopa and deep brain stimulation (DBS) decrease 
while motor symptoms improve (Priori et al. 2004). Some 
evidence suggests that this β activity, as well as β phase 
coupling to high-frequency oscillation amplitudes is a spe-
cific biomarker for the parkinsonian condition, (Wang et al. 
2016), but few studies have investigated these patterns in 
healthy controls (Swann et al. 2015).
Fig. 2  An abnormal microbiota 
in PD (in favour of proinflam-
matory species) can lead to 
immune dysregulation and 
intestinal nervous system 
inflammation and consequently 
to a dysfunctional intestinal bar-
rier: α-synuclein pathology can 
thus spread through the vagal 
nerve from peripheral auto-
nomic neurons in the gastroin-
testinal apparatus to the central 
nervous system. From Perez-
Pardo (https ://doi.org/10.1016/j.
ejpha r.2017.05.042) 2017 with 
permission from Elsevier
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Omics
During continued research into PD, the study of disease 
networks and molecular pathways through a bioinformatics 
approach provides new potential ‘Omics’ biomarkers.
Omics testing can be applied to various biological media 
(tissue, CSF, blood, urine) and aims to analyse functional 
molecules such as proteins (proteomics), DNA/RNA 
(genomics), lipids (lipidomics), carbohydrates (glycom-
ics) and metabolites (metabolomics), interactions between 
molecules (interactomics), potentially involved in pathways 
that are associated with dopaminergic neurodegeneration 
and subsequently PD (Redenšek et al. 2018).
Metabolomics refers to the study of quantitative data on 
cellular processes, molecular connections and metabolic 
pathways appearing in complex diseases such as neuro-
degenerative disorders. A recent review (Kori et al. 2016) 
reported that to date 54 metabolites have been studied as 
biomarkers for PD. Some of these metabolites were found 
disease-specific and others matched also with other neu-
rodegenerative diseases such as Alzheimer’s disease and 
amyotrophic lateral sclerosis. A more specific set of differ-
ent system biomarkers should be studied for PD diagnosis 
or prognosis or both.
In vivo brain metabolomics in PD can be studied noninva-
sively by magnetic resonance spectroscopy (MRS) measured 
in specified small tissue volumes in the brain; this technique 
is useful for increasing insight into the pathophysiological 
mechanisms underlying PD and may produce biomarkers for 
metabolic dysfunctions reflecting irreversible neuronal dam-
age (Davie 1998). This technique is based on the behaviour 
of specific nuclei within a magnetic field and on the princi-
ple that resonant frequencies depend on the chemical envi-
ronment around the nuclei. Clinical studies mainly focused 
on metabolites containing hydrogen (H MRS), providing 
information about the status of high-energy phosphates, and 
those containing phosphorus (31P MRS), reflecting intracel-
lular energy (Rango 2015). The extreme heterogeneity in 
these studies in number of enrolled patients and techniques 
used makes MRS, for the time being, only a future candidate 
in PD biomarker scenery (Fig. 4).
Fig. 3  7-Tesla magnetic resonance imaging scan (MRI) scan show-
ing mesencephalic anatomy in a control (C) and a patient with Par-
kinson’s disease (PD). Nigrosome-1 (white arrowheads) appears as a 
hyperintense pocket (due to a low iron content) in the control subject 
whereas it is not visible in the PD patient, in whom shape analysis 
shows undulation in the anterolateral perimeter of the subthalamic 
nucleus (arrow). From Lehéricy et  al. (https ://doi.org/10.1002/
mds.26043 ), 2014 with permission from John Wiley and Sons
Fig. 4  Genetic risk factors for Parkinson’s disease. Parkinson’s dis-
ease (PD) has a multifactorial genesis and, although only about 10% 
of patients have a family history, at least 30% of the risk of PD devel-
oping depends on genetic factors, which differ in strength and allele 
frequencies. The size of the bubbles corresponds to population; the 
size of the rings corresponds to allele frequencies; inheritance is 
shown by colours (blue = dominant, yellow = recessive, green = risk 
loci). From Gasser (https ://doi.org/10.3233/JPD-14050 7) 2015 with 
permission of IOS Press
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Inflammation
Animal and human studies supported the role of inflamma-
tion in PD, due to the abnormal protein misfolding, which 
can activate a proinflammatory state involving both Th1 and 
Th2 responses (Mosley et al. 2012) and microglial activa-
tion (Qian and Flood 2008). This inflammatory activation 
depends also on interactions between aging, environmental 
risk factors and genetic factors. Dopaminergic drugs can 
modify the biological characteristics of T lymphatic cells 
dopamine receptors, by inhibiting the release of cytotoxic 
mediators involved in PD development. In their review illus-
trating immune dysregulation and inflammation response 
(Chen et al. 2016) Chen et al. identified several potential PD 
biomarkers: immunological genes (such as some human leu-
kocyte antigen genes), PD-related genes (directly influencing 
α-synuclein accumulation), PD-related microRNAs (which 
modulate PD genes at a post-transcriptional level), specific 
antibodies (such as elongation factor 1-alpha-1 and poly (A) 
binding protein cytoplasmic-3), inflammatory factors (such 
as cytokines). Increased interleukin-6 and -8 levels indicate a 
risk of PD (Polivka et al. 2016); higher levels of soluble TNF 
receptor-1 were linked to early onset PD (Scalzo et al. 2010).
Among the various available PET radiotracers for imag-
ing microglia, the most currently used is the 18 kDa trans-
locator protein (TSPO), overexpressed on the outer mito-
chondrial membrane of the activated microglia, but usually 
poorly expressed in healthy brains (Gerhard 2016). Previ-
ous studies showed how microglia activation patterns dif-
fered in distinct parkinsonian syndromes according to how 
neuropathologic changes are distributed in these disorders, 
suggesting a role of a disease specific marker. Longitudinal 
studies are needed to estimate the association between bio-
marker evidence for microglial activation with and clinical 
disease progression in PD. Whether and if so how microglial 
activation relates to neurodegeneration in PD is an interest-
ing question that deserves future research.
Conclusion
Identifying a successful biomarker depends inevitably on 
fully understanding the pathophysiology underlying the 
disease. In PD, despite remarkable advances in our insight 
into the responsible mechanisms, the aetiology remains 
unknown. This drawback makes the search for diagnostic 
or preclinical biomarkers especially complex to achieve. 
Intense research efforts aim now to find multiple biomarkers 
to detect PD as early as possible and to distinguish it from 
other parkinsonisms. Although this evaluative review sum-
marises research that takes the field ahead, given the abun-
dant research it inevitably leaves some studies unmentioned. 
Given that the diagnosis of PD is still based on clinical find-
ings, a single test seems unlikely to satisfy all the functions 
required by a reliable biomarker for PD. Current research 
now aims to strengthen the diagnosis of PD by combining 
various clinical or non-clinical biomarkers or both. A single 
biomarker could play one or multiple roles (preclinical, diag-
nostic, or prognostic) thus providing variable clinometric 
properties. A reliable putative biomarker should be repro-
ducible and replicable and take into account possible con-
founding from sociodemographic or other factors (McGhee 
et al. 2013). A feature that makes discovering a biomarker 
an even more complex undertaking is the clinical heteroge-
neity in PD from the early preclinical to the more advanced 
disease stages. Aggregation of certain symptoms in specific 
clusters (expressed by different phenotypic PD traits) may 
reflect degeneration in distinct neural pathways (Di Bat-
tista et al. 2018), a pathophysiological change that accounts 
for different expression and also disease progression. The 
variability in findings from biomarker studies might reflect 
recruiting a non-uniform PD population. Heterogeneity in 
PD could imply the need to seek specific diagnostic bio-
markers for variable PD traits, and consequently, different 
theragnostic markers. Research efforts to this aim may be 
very beneficial when research develops neuroprotective ther-
apies to slow or halt the progression of the disease. Despite 
advances in our insight into the pathogenesis and pathophys-
iology underlying PD, today the neurologist has no 100% 
reliable clinical marker for use in clinical practice and still 
needs to rely on clinical expertise to diagnose PD. This is 
the most pressing problem on which biomarker researchers 
need to focus their efforts in the coming years.
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